The discovery of GCC expression as a unique biomarker for detecting metastatic colorectal cancer has led to the development of the GCC Cancer Vaccine and GCC CAR-T cell therapeutics.

Click below to learn more to read about the clinical trials for these potential breakthrough therapies.

 

GCC Cancer Vaccine	GCC CAR-T
FDA phase I clinical trial complete; currently preparing for FDA phase IIa clinical trial	Preclinical trials completed; preparations for FDA phase I clinical trial are underway
Preclinical Study Phase I Trial Phase II Trial Design	Preclinical Study Phase I Trial